Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Incyte launches late-stage study assessing JAK1 inhibitor itacitinib in in GvHD

Published 07/20/2017, 10:00 AM
Updated 07/20/2017, 10:00 AM
© Reuters.  Incyte launches late-stage study assessing JAK1 inhibitor itacitinib in in GvHD
  • The first patient has been treated in Incyte's (INCY -0.2%) Phase 3 clinical trial, GRAVITAS-301, assessing JAK1 inhibitor itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GvHD).
  • The study will assess the combination of itacitinib and corticosteroids compared to placebo plus corticosteroids. The primary endpoint is overall response rate at day 28 as measured by CIBMTR (Center for International Blood and Marrow Transplant Research) response index.
  • According to ClinicalTrials.gov, the estimated primary completion date is April 2019. The estimated study completion date is March 2020.
  • Now read: Incyte Corporation (INCY) Presents At Nasdaq 36th Investor Program - Slideshow


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.